CSIMarket Company Name, Ticker, Competitors, else..
 
Silo Pharma Inc  (NASDAQ: SILO)
 
Price: $2.4000 $-0.05 -2.041%
Day's High: $2.5 Week Perf: -3.23 %
Day's Low: $ 2.20 30 Day Perf: -48.61 %
Volume (M): 35,500 52 Wk High: $ 15.15
Volume (M$): $ 0 52 Wk Avg: $6.21
Open: $2.45 52 Wk Low: $2.20



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 1
 Employees 3
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Silo Pharma Inc is a pharmaceutical company that focuses on developing psychedelic therapeutics to treat mental health disorders. They aim to explore the potential benefits of psychedelic compounds, such as psilocybin and LSD, in treating conditions like depression, anxiety, and PTSD. The company conducts research and clinical trials to understand the therapeutic effects of these substances on the brain and develop safe and effective treatments. Silo Pharma Inc is committed to bringing innovative solutions to address the unmet medical needs in the field of mental health using psychedelic medicine.


   Company Address: 560 Sylvan Avenue Englewood Cliffs 7632 NJ
   Company Phone Number: 400-9031   Stock Exchange / Ticker: NASDAQ SILO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Announcement

Silo Pharma Unveils Strategic Cryptocurrency Investment, Achieves Milestones in PTSD Treatment, and Launches $2.1 M...

Published Tue, Sep 16 2025 12:22 PM UTC

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company committed to innovating drug delivery systems and formulations, is making waves across different sectors of the healthcare and technology landscape. In a recent series of announcements, the company has outlined a comprehensive trajectory that includes an innovative cryptocurrency treasury strat...
Announcement

Silo Pharmas Strategic Shift Integrating Bitcoin as a Treasury Reserve to Enhance Financial Resilience

Published Thu, Jun 5 2025 3:58 PM UTC

In a significant development reflecting a broader trend among corporations, Silo Pharma Inc. has taken a bold step toward financial diversification by approving a purchase of $1 million in Bitcoin as a treasury reserve asset. This decision aims not only to enhance the company’s financial stability but also to position it favorably within the fast-evolving digital asset lan...
Contract

Silo Pharma and Sever Pharma Usher in a New Era of Pain Management with Innovative Ketamine Implant Therapy

Published Wed, Aug 14 2024 6:30 PM UTC

In recent developments within the realm of chronic pain management, Silo Pharma, a biopharmaceutical company dedicated to the development of innovative therapeutic solutions, has announced an expansion of its development agreement with Sever Pharma. This collaboration aims to enhance the research and development of SP-26, a groundbreaking dissolvable ketamine-based injectabl...
Stocks on the Move

Silo Pharma Inc. Ventures into Registered Direct Offering, Boosting Future Developments

Published Tue, Jul 23 2024 12:26 PM UTC

In recent news, Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company, has announced its entry into a $2.1 million Registered Direct Offering. This move marks a significant milestone for the company and demonstrates its commitment to advancing novel formulations and drug delivery techniques. The offering will fuel Silo Pharma s endeavors in develop...
Announcement

Silo Pharma Secures $2.1 Million in Funding to Drive Innovative Drug Development

Published Fri, Jul 19 2024 12:01 PM UTC

Silo Pharma Advancing Research and Development with $2.1 Million Registered Direct OfferingSarasota, FL - Silo Pharma, Inc. (Nasdaq: SILO), a prominent biopharmaceutical company specializing in innovative drug delivery systems for traditional therapeutics and psychedelic treatments, is making significant strides in its mission to revolutionize the field of healthcare. The co...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 48.69
Price to Sales (Expected) -
Price to Book 0.54
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.9
Working Capital Ratio 5.36
Leverage Ratio (MRQ) 0.22
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -5.94 $
Revenues (TTM) 0.05 $
Cash Flow (TTM) -
Cash 4.76 $
Book Value 4.45 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,490,661
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.